US SB142 | 2023-2024 | 118th Congress
Status
Spectrum: Slight Partisan Bill (Democrat 8-3)
Status: Introduced on January 30 2023 - 25% progression
Action: 2023-03-01 - Placed on Senate Legislative Calendar under General Orders. Calendar No. 20.
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on January 30 2023 - 25% progression
Action: 2023-03-01 - Placed on Senate Legislative Calendar under General Orders. Calendar No. 20.
Text: Latest bill text (Introduced) [PDF]
Summary
A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products.
Title
Preserve Access to Affordable Generics and Biosimilars Act
Sponsors
| Sen. Amy Klobuchar [D-MN] | Sen. Chuck Grassley [R-IA] | Sen. Richard Durbin [D-IL] | Sen. Kevin Cramer [R-ND] |
| Sen. Richard Blumenthal [D-CT] | Sen. Mark Kelly [D-AZ] | Sen. Chris Van Hollen [D-MD] | Sen. Cory Booker [D-NJ] |
| Sen. Jon Ossoff [D-GA] | Sen. Joni Ernst [R-IA] | Sen. Peter Welch [D-VT] |
History
| Date | Chamber | Action |
|---|---|---|
| 2023-03-01 | Senate | Placed on Senate Legislative Calendar under General Orders. Calendar No. 20. |
| 2023-03-01 | Senate | Committee on the Judiciary. Reported by Senator Durbin with an amendment in the nature of a substitute. Without written report. |
| 2023-02-09 | Senate | Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably. |
| 2023-01-30 | Senate | Read twice and referred to the Committee on the Judiciary. |
